Ulcerative Colitis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ulcerative Colitis Market Overview
The ulcerative colitis (UC) market size across the 8MM was valued at $7.3 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The symptoms of UC vary from person to person and may include diarrhea with blood or pus, passing blood with stool, abdominal pain & cramping, and tenesmus or urgency to defecate. UC can occur at any age, although most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women.
The ulcerative colitis market research report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and Canada) and provides an Excel-based forecast model for the UC market through 2031.
Ulcerative Colitis Market Outlook, 2021-2031 ($ Billion)
To gain more information about the ulcerative colitis market forecast, download a free report sample
Ulcerative Colitis Market Drivers
Some of the major drivers of growth in the ulcerative colitis market across the 8MM over the forecast period will include the increase in prevalence rates, and the approval and launch of 11 pipeline products. Growth in the UC market is also expected to be driven by the high treatment rates across the 8MM and the high unmet need for safe efficacious therapies.
Ulcerative Colitis Market Segmentation by Class
Some of the key classes in the US ulcerative colitis market are Aminosalicylates, Steroids, Immunomodulators, Anti TNF-Biologics, Anti-Interleukin Biologics, Anti-Integrins, Biosimilars, JAK inhibitors, S1P1 receptor modulator, and LANCL2 agonist.
There are five marketed biologics in the US for UC: the three TNF inhibitors (Remicade, Humira, and Simponi), an IL-12/IL23 inhibitor (Stelara), and an integrin inhibitor (Entyvio). In 2021, Entyvio was the market-leading biologic for UC in the US. BMS’ Zeposia launched in 2022, and it is expected to eat into the patient share of both the immunomodulators and the current biologics. Due to the safety concerns surrounding JAK inhibitors, the S1P receptor modulators could gain an advantage in the market.
For more class insights into the US ulcerative colitis market, download a free report sample
Ulcerative Colitis Market - Competitive Landscape
Some of the leading players in the UC market are AbbVie, Abivax, Bristol Myers Squib, Boehringer Ingelheim, EA Pharma, Eli Lilly, Galapagos, Gilead, InDex Pharmaceuticals, Janssen, Pfizer, Protagonist Therapeutics, and Takeda.
Ulcerative Colitis Market Report Overview
Market Size (2021) | $7.3 billion |
CAGR (2021 – 2031) | >2% |
Key Class | Aminosalicylates, Steroids, Immunomodulators, Anti TNF-Biologics, Anti-Interleukin Biologics, Anti-Integrins, Biosimilars, JAK inhibitors, S1P1 receptor modulator, and LANCL2 agonist |
Leading Players | AbbVie, Abivax, Bristol Myers Squib, Boehringer Ingelheim, EA Pharma, Eli Lilly, Galapagos, Gilead, InDex Pharmaceuticals, Janssen, Pfizer, Protagonist Therapeutics, and Takeda |
Scope
This report provides:
- Overview of ulcerative colitis, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized ulcerative colitis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ulcerative colitis market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ulcerative colitis treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global ulcerative colitis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ulcerative colitis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ulcerative colitis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Abivax
Bristol Myers Squib
Boehringer Ingelheim
EA Pharma
Eli Lilly
Galapagos
Gilead
InDex Pharmaceuticals
Janssen
Pfizer
Protagonist Therapeutics
Takeda
Table of Contents
Frequently asked questions
-
What was the ulcerative colitis market size across the 8MM in 2021?
The ulcerative colitis market size across the 8MM was valued at $7.3 billion in 2021.
-
What is the ulcerative colitis market growth rate?
The ulcerative colitis market is expected to achieve a CAGR of more than 2% during 2021-2031.
-
What are some of the key classes in the US ulcerative colitis market?
Some of the key classes in the US ulcerative colitis market are Aminosalicylates, Steroids, Immunomodulators, Anti TNF-Biologics, Anti-Interleukin Biologics, Anti-Integrins, Biosimilars, JAK inhibitors, S1P1 receptor modulator, and LANCL2 agonist.
-
Who are the leading players in the UC market?
Some of the leading players in the UC market are AbbVie, Abivax, Bristol Myers Squib, Boehringer Ingelheim, EA Pharma, Eli Lilly, Galapagos, Gilead, InDex Pharmaceuticals, Janssen, Pfizer, Protagonist Therapeutics, and Takeda.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Ulcerative Colitis reports

